Intractable Intracranial Tuberculous Infection Responsive to Thalidomide: Report of Four Cases

Abstract

Paradoxical enlargement and development of new intracranial tuberculomas and tuberculous brain abscesses on adequate antituberculosis treatment are well recognized and supposedly cytokine mediated. These lesions are often unresponsive to conventional antituberculosis treatment, corticosteroids, and surgery. We therefore assessed the effect of adjunctive thalidomide, a tumor necrosis factor α—modulating drug, in intractable intracranial tuberculosis that did not respond to standard medical and surgical therapy. Four consecutive children (three children with bacteriologic proof and one child with clinical evidence of intracranial tuberculosis) were studied. Three patients each had a giant tuberculous abscess, and the fourth had chronic basal arachnoiditis with progressive loss of vision. Three of the four patients had relentless neurologic deterioration, and all showed disease progression on neuroimaging despite full medical and appropriate surgical treatment. Marked clinical and neuroradiologic improvement occurred after thalidomide was added to the antituberculosis treatment regimen of these four patients. Adjunctive thalidomide might have a role in the management of intractable intracranial tuberculosis and needs further investigation in this regard. (J Child Neurol 2 0 0 6; 2 1: 3 0 1 — 3 0 8; DOI 10.2310/7010.2006.00071).

Get full access to this article

View all access options for this article.

References

Afghani B. , Lieberman JM : Paradoxical enlargement or development of intracranial tuberculomas during therapy: Case report and review. Clin Infect Dis 1994;19:1092—1099.

Chambers ST , Hendrickse WA , Record C. , et al: Paradoxical expansion of tuberculomas during chemotherapy. Lancet 1984;2:181—183.

De Castro CC , de Barros NG , de Sousa Campos ZM , Cerri GG : CT scans of cranial tuberculosis. Radiol Clin North Am 1995;33: 753—769.

Gropper MR , Schulder M. , Sharan AD , Cho E. : Central nervous system tuberculosis: Medical management and surgical indications . Surg Neurol 1995;44:378—385.

Henrickson M. , Weisse ME : Tuberculous brain abscess in a three-year-old South Pacific Islander. Pediatr Infect Dis J 1992;11: 488—491.

Tsenova L. , Sokol K. , Freedman VH , Kaplan G. : A combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998;177:1563—1572.

Schoeman JF , Ravenscroft A. , Hartzenberg HB : Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess. Childs Nerv Syst 2001;17: 370—372.

Roberts Mtm , Mendelson M. , Meyer P. , et al: The use of thalidomide in the treatment of intracranial tuberculomas . J Infect 2003;47:251—255.

Schoeman JF , Springer P. , Janse van Rensburg A. , et al: Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study. J Child Neurol 2004; 19: 250—257.

10.

Schoeman JF , Donald PR , Van Zyl LE , Laubscher JA : Serial CT scanning in childhood tuberculous meningitis: Prognostic features in 198 cases. J Child Neurol 1995; 10: 320—32 9.

11.

Rao GO , Nadh BR , Hemaratnan A. , et al: Paradoxical progression of tuberculous lesions during chemotherapy of central nervous system tuberculosis. J Neurosurg 1995;83:359—362.

12.

Schoeman JF , Van Zyl LE , Laubscher JA , Donald PR : Effect of corticosteroids on intracranial pressure, computerized tomographic findings, and clinical outcome in young children with tuberculous meningitis . Pediatrics 1997;99:226—231.

13.

Garg RK : Tuberculosis of the central nervous system. J Postgrad Med 1999;75:133—140.

14.

Donald PR , Schoeman JF , Beyers N. , et al: Concentrations of interferon-γ, tumor necrosis factor-α and interleukin 1 in the cerebrospinal fluid of children treated for tuberculous meningitis. Clin Infect Dis 1995;21:924—929.

15.

Schoeman JF , Springer P. , Ravenscroft A. , et al: Adjunctive thalidomide therapy of childhood tuberculosis meningitis: A possible antiinflammatory role. J Child Neurol 2000;15:497—503.

16.

Sampaio EP , Sarno EN , Galilly R. , et al: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:1675—1680.

17.

Klausner JD , Makonkawkeyoon S. , Akarasewi P. , et al: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247—257.

18.

Tramontana JM , Utaipat U. , Moloy A. , et al: Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384—397.

19.

Gori A. , Rossi MC , Trabattoni D. , et al: Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection . J Infect Dis 2000;182:639—40.

20.

Bekker LG , Haslett PA , Maartens G. , et al: Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type I and tuberculosis. J Infect Dis 2000;181:954—965.

21.

Haslett PA , Corral LG , Albert M. , Kaplan G. : Thalidomide co-stimulates primary human T lymphocytes preferentially i n d u c i n g p r o l i f e r a t i o n, c y t o k i n e p r o d u c t i o n a n d cytotoxic responses in the CD8+ subset. J Exp Med 1998;187: 1885—1892.

22.

Marriott JB , Clarke IA , Dredge K. , et al: Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002; 130: 75—84.

23.

Cavaletti G. , Beronio A. , Reni L. , et al: Thalidomide sensory neuro-toxicity: A clinical and neurophysiological study. Neurology 2004;62:2291—2293.